Bausch Health Companies Inc.: Keratoconjunctivitis Sicca trials

The registry lists 14 Keratoconjunctivitis Sicca studies with Bausch Health Companies Inc. as lead sponsor. 0 are open to participants now and 9 have results posted.

Phase 2 7Phase 3 4Phase 4 1No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Effect of NOV03 on Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Mojave Study)CompletedNCT04567329Phase 3Results posted
• Perfluorohexylcotane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Gobi Study)CompletedNCT04139798Phase 3Results posted
• A Study to Evaluate the Performance and Safety of CBL-102 Versus Vismed® Multi Eye Drops in the Management of Dry EyeCompletedNCT03368404Not applicableResults posted
• A Study to Evaluate the Performance and Safety of CBL-101 Versus Vismed® Multi Eye Drops in the Management of Dry EyeCompletedNCT02975102Not applicableResults posted
• Lotemax® Gel 0.5% and Restasis 0.05% in Participants With Mild or Moderate Keratoconjunctivitis Sicca (Dry Eye Disease)CompletedNCT01817582Phase 2Results posted
• A Dose Ranging Study to Evaluate Safety and Efficacy of Bromfenac Ophthalmic Solution in Dry Eye DiseaseCompletedNCT01212471Phase 3Results posted
• Study to Assess the Safety and Efficacy of BOL-303242-X Ophthalmic Suspension in Dry Eye SyndromeCompletedNCT01163643Phase 2Results posted
• Safety and Efficacy of an Ophthalmic Solution in Dry Eye DiseaseCompletedNCT00758784Phase 2Results posted
• Efficacy Study of Ecabet Ophthalmic Solution in Dry Eye DiseaseCompletedNCT00667004Phase 2Results posted
• A Study to Evaluate Corneal Endothelial Cell Density (ECD) in Subjects With Dry Eye Disease (DED) Administering Miebo® (Perfluorohexyloctane Ophthalmic Solution) for 12 Months.Active, not recruitingNCT06565650Phase 4
• A Study to Evaluate the Performance and Safety of Artelac Rebalance® Versus Vismed in the Management of Dry EyeWithdrawnNCT01791426Not applicable
• Loteprednol Etabonate Opthalmic Suspension for the Treatment of Dry EyeCompletedNCT00560638Phase 2
• Efficacy and Safety Study for Ecabet Ophthalmic Solution for Treating Dry Eye SyndromeCompletedNCT00370747Phase 2
• Efficacy and Safety Study for Ecabet Ophthalmic Solution for Treating Dry Eye SyndromeCompletedNCT00198536Phase 2/3